ClinicalTrials.gg
CompletedNCT00356122Updated Oct 17, 2011Results posted

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Docetaxel and Oxaliplatin in Non-Small Cell Lung Cancer, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-17.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
87th of 188
53 · median 50
Started
2006
with 7 others
Phase 2
125 of 198
9 open now
Registered
72nd of 198
by date
Lead sponsor
7 of 198
Sanofi

Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 87th largest by enrollment of the 188 interventional ones that give a count, is one of 8 that started in 2006, is one of 125 in phase 2, and was the 72nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease. This study provided a new combination of chemotherapy drugs - docetaxel and oxaliplatin - as first line therapy in the treatment of lung cancer. The therapy included bevacizumab that may prevent or slow down the blood supply to the tumor and may also prevent tumor growth. The three investigational drugs are United States Food and Drug Administration (FDA) approved.

Read the detailed description

The planned treatment duration for each participant is six 21-day treatment cycles of combination therapy; non-progressing participants will continue on bevacizumab monotherapy until progression. After discontinuation or after completion of all study treatments, all participants will be contacted every 3 months for a maximum of 2 years from first treatment to document overall survival and record new anticancer treatment (chemotherapy or biologic).

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Lung
  • non-small cell
  • chemotherapy
  • tumor
  • advanced
  • recurrent
  • metastatic
  • Non-Small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who met all of the following criteria during screening were considered for enrollment into the study:

  1. Had the in writing for all prior to registration into the study
  2. Had histologic or cytologic confirmation of locally advanced or (stage IIIb/IV) NSCLC (non-squamous histology). Participants with mixed tumor types could have been enrolled, unless small cell elements were discovered
  3. Had , defined as at least 1 lesion that could be accurately measured in at least 1 dimension (longest diameter) as ≥ 2.0 cm with conventional computerized tomography (CT) or magnetic resonance imaging (MRI) scans, or as ≥ 1.0 cm with spiral CT scan
  4. Had no prior systemic chemotherapy
  5. Was male or female ≥ 18 years old
  6. Had an estimated life expectance of ≥ 12 weeks
  7. Had an performance status (PS) of 0, 1, or 2
  8. Was a nonpregnant, nonlactating female Was a male or female of who was willing to use an effective form of while on therapy and for 90 days thereafter.
  9. Had adequate renal function as determined by the following within 2 weeks prior to study registration.

    • A calculated greater than 45 mL/min using the Cockcroft-Gault formula
    • A urine dipstick or urinalysis for protein \<2+ (Participants discovered to have ≥ 2+ proteinuria on dipstick or urinalysis at baseline had to undergo a 24 hour urine collection and had to have ≤ 1 gm of protein over 24 hours to be eligible).
  10. Had a hematologic evaluation within 2 weeks prior to study registration (and met the minimum values):

    • Had (ANC) ≥ 1,500 cells/microL
    • Had count ≥ 100,000 cells/microL
    • Had ≥ 9.9 gm/deciL (erythropoietin [e.g., Epogen®] could have been used to maintain or exceed this level)
    • Had a (PTT) ≤ (ULN)
  11. Had a hepatic function evaluation within 2 weeks prior to study registration met the eligibility criteria for , (AST), alanine aminotransferase (ALT), and alkaline phosphatase.

Exclusion criteria

Exclusion criteria

Participants with any of the following were not included in the study:

  1. Had received prior systemic chemotherapy or vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) inhibitor therapy at any time; or had received recent or current radiation therapy
  2. Had intrathoracic lung carcinoma of squamous cell histology. (Participants with extrathoracic-only squamous cell NSCLC were eligible. Participants with only peripheral lung lesions (of any NSCLC histology) were also eligible
  3. Had cardiovascular diseases and related treatment, including the following:

    • Class ≥ 2 congestive heart failure; participants with a history of serious cardiac disease not adequately controlled; or a history of myocardial infarction or unstable angina pectoris within 6 months prior to study registration
    • History of stroke or within 6 months of study registration
    • History of hypertensive crisis or hypertensive encephalopathy
    • History of thrombotic or hemorrhagic disease
    • Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)
    • peripheral vascular disease, or arrhythmia
    • Inadequately controlled blood pressure (defined as systolic blood pressure >150 mm Hg and/or diastolic blood pressure >100 mm Hg)
    • Significant vascular disease (e.g., aortic aneurysm, aortic dissection) within 6 months prior to study registration
    • Therapeutic anticoagulation (Participants receiving prophylactic anticoagulation for venous access devices were allowed providing they met certain criteria)
    • Chronic daily treatment with aspirin (≥ 325 mg/day) or nonsteroidal anti-inflammatory agents known to inhibit function; treatment with dipyridamole, ticlopidine, clopidogrel, or cilostazol was not allowed.
  4. Had a surgical procedure in anamnesis (medical history):

    • Major surgical procedure, open , or significant traumatic injury within 4 weeks prior to study registration, or anticipation of need for major surgical procedure during the course of the study
    • In the case of high-risk procedures, such as liver resection, thoracotomy, or neurosurgery, within 8 weeks prior to study registration
    • Minor surgical procedures (e.g., fine needle aspirations, core biopsies) within 7 days prior to registration
  5. Had a serious nonhealing wound, active ulcer, or untreated bone fracture
  6. Had a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study registration
  7. Had a history of gross hemoptysis (defined as bright red blood of ≥ 0.5 teaspoon) within 4 weeks prior to study registration
  8. Had a history of reaction to drugs formulated with polysorbate 80 or platinum containing compounds
  9. Had peripheral neuropathy ≥ Grade 2 (based on v3.0)
  10. Had known central nervous system (CNS) disease, except for treated . However, participants with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to study registration were excluded.
  11. Had a history of a other than NSCLC; exceptions to this included:

    • Curatively treated basal cell carcinoma, cervical intraepithelial neoplasia, or localized prostate cancer with a current prostate-specific antigen (PSA) of less than 1.0 ng/dL on 2 successive evaluations at least 3 months apart, and the most recent evaluation being within 4 weeks of study registration
    • History of another malignancy that was curatively treated and no evidence of disease for a minimum of 5 years
  12. Had symptoms of a clinically meaningful illness in the 90 days before study registration, or had history of other disease, (such as [HIV] positive, chronic infection [e.g., pulmonary tuberculosis], or hepatitis A, B, or C [active or previously treated]), had an active infection with fever, had metabolic dysfunction, had physical examination finding, or had clinical a laboratory finding giving reasonable suspicion of a disease or condition that the use of an drug, that might affect the interpretation of the results of the study, or render the participant at high risk from treatment complications; (testing for these conditions was at investigator discretion)
  13. Had a mental condition rendering the participant unable to understand the nature, scope, and possible consequences of the study

The above information is not intended to contain all considerations relevant to a patients potential participation in a clinical trial.

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Docetaxel/Oxaliplatin/Bevacizumab

    Participants with advanced, recurrent, or metastatic Non Small Cell Lung Cancer (NSCLC), treated with the combination of docetaxel, followed by oxaliplatin, and then bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.

    Drug: Docetaxel · Drug: Oxaliplatin · Drug: Bevacizumab

Interventions

  • 70 mg/m\^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)

  • 100 mg/m\^2 administered IV on Day 1 for Cycles 1-6

  • 15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the interval from the date of registration to the earliest date of documented evidence of progressive disease, or the date of death due to any cause, whichever occurred first. Progressive disease occurred when the participant had at least a 20% increase in the sum of the longest diameter (LD) of target lesions, compared to the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions.

    Time frame: Baseline to PFS (up to 24 months after the first treatment)

Secondary outcomes

  1. Objective Response Rate

    Objective response rate is the percentage of participants with an objective response. Improvements in tumor measurements from baseline values were assigned a status of Complete Response (CR) or Partial response (PR) based on the Response Evaluation Criteria in Solid Tumors (RECIST). Overall objective response was the sum of CR and PR. CR referred to the disappearance of all target lesions, and PR was at least 30% decrease in the sum of the longest diameter (LD) of target lesions, compared to the baseline sum LD. Responses were confirmed by repeat assessments within 4 to 6 weeks.

    Time frame: Baseline to CR or PR (up to 24 months after the first treatment)

  2. Time-to-treatment Failure (TTF)

    Treatment failure was defined as an event which lead to the participant's withdrawal from the study treatment due to lack of efficacy, disease progression, adverse events, or due to a participant's request as recorded in the Case Report Form (CRF), death, or use of other anticancer therapy. TTF was assessed using Kaplan-Meier method, and the median TTF with 95% CIs was computed using the Brookmeyer and Crowley method.

    Time frame: Baseline to treatment failure (up to 24 months after the first treatment)

  3. Overall Survival (OS)

    OS was measured from the date of registration to the date of death due to any cause, or to the date of last contact (for censored observations). OS was assessed by the Kaplan-Meier method and the estimates of median survival time with 95% CI are reported.

    Time frame: Baseline to OS (up to 24 months after the first treatment)

  4. Number of Participants With Treatment-related Toxicities

    Treatment-related toxicities were serious and non-serious adverse events (AE) considered related to study treatment by the investigator. AEs were any unfavorable and unintended signs, symptoms, syndromes, or illnesses that developed or worsened during the observation period, and included abnormal results from diagnostic procedures. Serious AEs resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, appeared as a congenital anomaly or were considered medically important by the investigator.

    Time frame: From baseline up to 30 days after treatment discontinuation

07

Results

Posted Sep 16, 2011

Participant flow

The study was initiated in 18 sites in the United States, of which 14 sites enrolled a total of 85 participants.

TREATMENT
Participant flow — TREATMENT
MilestoneDocetaxel/Oxaliplatin/Bevacizumab
Started53
Completed8
Not completed45
Withdrew: Lack of efficacy26
Withdrew: Adverse event10
Withdrew: Subject's request4
Withdrew: Other4
Withdrew: Did not receive study medication1
FOLLOW-UP
Participant flow — FOLLOW-UP
MilestoneDocetaxel/Oxaliplatin/Bevacizumab
Started53
Completed12
Not completed41
Withdrew: Death37
Withdrew: Lost to follow-up2
Withdrew: Other2

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was defined as the interval from the date of registration to the earliest date of documented evidence of progressive disease, or the date of death due to any cause, whichever occurred first. Progressive disease occurred when the participant had at least a 20% increase in the sum of the longest diameter (LD) of target lesions, compared to the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions.

Time frame:
Baseline to PFS (up to 24 months after the first treatment)
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsDocetaxel/Oxaliplatin/Bevacizumab
Progression-free Survival (PFS)5.6 (3.7 to 7.6)
SecondaryObjective Response Rate

Objective response rate is the percentage of participants with an objective response. Improvements in tumor measurements from baseline values were assigned a status of Complete Response (CR) or Partial response (PR) based on the Response Evaluation Criteria in Solid Tumors (RECIST). Overall objective response was the sum of CR and PR. CR referred to the disappearance of all target lesions, and PR was at least 30% decrease in the sum of the longest diameter (LD) of target lesions, compared to the baseline sum LD. Responses were confirmed by repeat assessments within 4 to 6 weeks.

Time frame:
Baseline to CR or PR (up to 24 months after the first treatment)
Reported as:
Mean · Percentage of participants
Objective Response Rate
Percentage of participantsDocetaxel/Oxaliplatin/Bevacizumab
Objective Response Rate30.2 (18.3 to 44.3)
SecondaryTime-to-treatment Failure (TTF)

Treatment failure was defined as an event which lead to the participant's withdrawal from the study treatment due to lack of efficacy, disease progression, adverse events, or due to a participant's request as recorded in the Case Report Form (CRF), death, or use of other anticancer therapy. TTF was assessed using Kaplan-Meier method, and the median TTF with 95% CIs was computed using the Brookmeyer and Crowley method.

Time frame:
Baseline to treatment failure (up to 24 months after the first treatment)
Reported as:
Median · Months
Time-to-treatment Failure (TTF)
MonthsDocetaxel/Oxaliplatin/Bevacizumab
Time-to-treatment Failure (TTF)4.7 (2.9 to 5.6)
SecondaryOverall Survival (OS)

OS was measured from the date of registration to the date of death due to any cause, or to the date of last contact (for censored observations). OS was assessed by the Kaplan-Meier method and the estimates of median survival time with 95% CI are reported.

Time frame:
Baseline to OS (up to 24 months after the first treatment)
Reported as:
Median · Months
Overall Survival (OS)
MonthsDocetaxel/Oxaliplatin/Bevacizumab
Overall Survival (OS)14.0 (9.9 to 16.9)
SecondaryNumber of Participants With Treatment-related Toxicities

Treatment-related toxicities were serious and non-serious adverse events (AE) considered related to study treatment by the investigator. AEs were any unfavorable and unintended signs, symptoms, syndromes, or illnesses that developed or worsened during the observation period, and included abnormal results from diagnostic procedures. Serious AEs resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, appeared as a congenital anomaly or were considered medically important by the investigator.

Time frame:
From baseline up to 30 days after treatment discontinuation
Reported as:
Number · Participants
Number of Participants With Treatment-related Toxicities
ParticipantsDocetaxel/Oxaliplatin/Bevacizumab
At least one AE related to docetaxel51
At least one AE related to oxaliplatin50
At least one AE related to bevacizumab43

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel/Oxaliplatin/Bevacizumab—17/52 (32.7%)51/52 (98.1%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventDocetaxel/Oxaliplatin/Bevacizumab
PNEUMONIAInfections and infestations4/52
ABDOMINAL PAINGastrointestinal disorders3/52
FEBRILE NEUTROPENIABlood and lymphatic system disorders2/52
SUPRAVENTRICULAR TACHYCARDIACardiac disorders2/52
DIARRHOEAGastrointestinal disorders2/52
SEPSISInfections and infestations2/52
DEHYDRATIONMetabolism and nutrition disorders2/52
ATRIAL FIBRILLATIONCardiac disorders1/52
INTESTINAL PERFORATIONGastrointestinal disorders1/52
LARGE INTESTINE PERFORATIONGastrointestinal disorders1/52
Most frequent other events
Showing 10 of 65
Most frequent other events
EventDocetaxel/Oxaliplatin/Bevacizumab
FATIGUEGeneral disorders37/52
DIARRHOEAGastrointestinal disorders33/52
NAUSEAGastrointestinal disorders32/52
ALOPECIASkin and subcutaneous tissue disorders24/52
VOMITINGGastrointestinal disorders21/52
ANOREXIAMetabolism and nutrition disorders15/52
INSOMNIAPsychiatric disorders14/52
CONSTIPATIONGastrointestinal disorders13/52
PYREXIAGeneral disorders12/52
COUGHRespiratory, thoracic and mediastinal disorders12/52

Baseline characteristics

Age Continuous
Age Continuous(years)Docetaxel/Oxaliplatin/Bevacizumab
Mean61.10 ± 11.07
Age, Customized
Age, Customized(participants)Docetaxel/Oxaliplatin/Bevacizumab
<65 years28
>=65 years25
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel/Oxaliplatin/Bevacizumab
Female15
Male38
Weight
Weight(kilograms)Docetaxel/Oxaliplatin/Bevacizumab
Mean76.530 ± 17.793
Height
Height(Centimeters)Docetaxel/Oxaliplatin/Bevacizumab
Mean169.80 ± 9.57
Body Surface Area (BSA)
Body Surface Area (BSA)(Square meters)Docetaxel/Oxaliplatin/Bevacizumab
Mean1.875 ± 0.252
08

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2006
First posted
Jul 25, 2006
Start
Jul 2006
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Results first posted
Sep 16, 2011
Last update
Oct 17, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00356122
Lead sponsor
Sanofi
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Jul 25, 2006
Start date
Jul 2006
Primary completion
Aug 2010
Completion
Aug 2010
Results posted
Sep 16, 2011
Last update
Oct 17, 2011

Study contacts

Vicki Erickson, MSN
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Oxaliplatin · Bevacizumab

Start the discussion